Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Arcapta Neohaler, Onbrez Breezhaler
Synonyms :
indacaterol
Class :
Drugs for asthma and COPD & Bronchodilators (Beta2-agonists/ Adrenergic agonists)
Dosage Forms & Strengths
Capsule, Inhalation:
75 mcg/capsule
Chronic Obstructive Pulmonary Disease (COPD)
1 capsule (75 mcg) is inhaled once a day
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
QTc interval is increased both by lenvatinib and indacaterol
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may increase the toxic effect of beta2 agonists
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
It may enhance the metabolism when combined with dexamethasone
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
It may enhance the risk of adverse effects when combined with bronchodilator
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
spironolactone and hydrochlorothiazide
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
may decrease the bronchodilatory effect of beta blockers
may have an increased tachycardic effect when combined with beta2-agonists
atosiban: they may increase the toxic effect of Beta2-Agonists
theophylline derivatives: they may increase the toxic effect of Beta2-Agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
Action:
Indacaterol is a long-acting β2-adrenergic receptor agonist (LABA) used primarily for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by stimulating β2-adrenergic receptors in the smooth muscle lining the airways, leading to muscle relaxation and sustained bronchodilation. This mechanism improves airflow, reduces breathlessness, and helps control chronic symptoms associated with COPD.
Spectrum
Indacaterol is indicated for the treatment of moderate to severe COPD, including conditions such as chronic bronchitis and emphysema.
Frequency defined:
1%-10%
Chest pain (2%)
Anxiety (2%)
Headache
Voice disorder
Diarrhea
Pruritis
Skin rash
Muscle cramps
Tremor
Abdominal pain
Vomiting
Nausea
Fever
<1%:
Angina pectoris
Cardiac arrhythmia
Cough
Dermatitis
Fatigue
Variable blood pressure
Restlessness
Nervousness
Long-acting β2-adrenergic agonists (LABAs) have been associated with an increased risk of asthma-related death. Evidence from a large, placebo-controlled clinical trial conducted in the United States found that patients who received salmeterol, another LABA, in addition to their standard asthma treatment had a higher incidence of asthma-related mortality compared to those receiving placebo. This elevated risk observed with salmeterol is considered to reflect a class-wide effect applicable to all LABAs, including indacaterol.
Contraindication:
Hypersensitivity
Primary Asthma Therapy (as Monotherapy)
Acute Episodes of Bronchospasm
Pregnancy consideration: No adverse effects were reported in animal studies with indacaterol.
Lactation: Excretion of indacaterol in breast milk is not known.
Pregnancy category:
Pharmacology
Indacaterol is a long-acting β2-adrenergic receptor agonist (LABA) used primarily for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It acts by stimulating β2-receptors in the bronchial smooth muscle, leading to prolonged bronchodilation.
Pharmacokinetics:
Absorption
Indacaterol typically reaches its peak serum concentration about 15 minutes after inhalation, whether administered once or repeatedly. Its absolute bioavailability following inhalation averages between 43% and 45%.
Distribution
Following intravenous infusion, indacaterol demonstrated a large volume of distribution (Vz), ranging from 2,361-2,557 L, suggesting widespread distribution throughout the body.
Metabolism
In vitro studies identified UGT1A1 as the sole UGT enzyme involved in converting indacaterol to its phenolic O-glucuronide form. Additionally, CYP3A4 was found to be the main enzyme responsible for indacaterol’s hydroxylation.
Excretion and Elimination
Indacaterol is mainly eliminated through feces, with about 54% of the administered dose recovered as the unchanged drug and approximately 23% as hydroxylated metabolites.
Indacaterol is administered through oral inhalation using a dry powder inhaler (DPI) device. It is intended for once-daily maintenance therapy in patients with chronic obstructive pulmonary disease (COPD).
Patient information leaflet
Generic Name: Indacaterol
Pronounced: in-da-KAT-eh-rol
Why do we use Indacaterol?
Indacaterol is a long-acting β2-adrenergic agonist (LABA) used primarily for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including conditions such as chronic bronchitis and emphysema. It is designed for once-daily use and works by relaxing the smooth muscles in the airways, leading to sustained bronchodilation and improved airflow. This helps reduce symptoms like breathlessness, enhance lung function, and decrease the frequency of COPD exacerbations.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
